Clinical Trial

A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is evaluating the efficacy and safety of Lianxiaxiaopi Granules in participant population. The main questions it aims to answer are: 1. Based on the Response rate of postprandial distress syndrome participants, evaluate whether the efficacy of Lianxiaxiaopi Granules is superior to placebo. 2. Evaluate the efficacy of Lianxiaxiaopi Granules in improving symptom of postprandial distress syndrome. 3. Evaluating the safety of Lianxiaxiaopi Granules in postprandial distress syndrome participants.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-17; most recent amendment 2026-01-15.
Status change: Not Yet Recruiting → Recruiting 2025-06-01
Trial Details
NCT Number NCT06696261
Lead Sponsor Tasly Pharmaceutical Group Co., Ltd
Conditions Postprandial Distress Syndrome
Enrollment 342 participants
Start Date 2025-02-27
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-20